External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

WCLC 2022

-
Coming soon
08:30 AM
Duration 10mins Hall C1
IMpower010: overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC
Enriqueta Felip, Nasser Altorki, Eric Vallieres, Ihor O. Vynnychenko, Andrey Akopov, Alex Martinez-Marti, Antonio Chella, Igor Bondarenko, Shunichi Sugawara, Yun Fan, Hirotsugu Kenmotsu, Yuh-Min Chen, Yu Deng, Meilin Huang, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, CaicunZhou, Heather A. Wakelee

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:00 PM
Duration 10mins Strauss 3
T-cell dynamics in response to neoadjuvant atezolizumab in early NSCLC by antigen response and T-cell receptor sequencing
Oezkan F, Hilz S, Grindheim J, Wallace A, Seweryn M, Reuben A, Zhang J, Owen DH, Nicholas A, Yadav M, Nagarkar D, De Almeida P, Ebert P, Osborne E, Johnson A, Lee JM, Bunn P, Johnson BE, Chaft J, Kris MG, Rusch VW, Schulze K, Kwiatkowski DJ, Wistuba II, Carbone DP

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:07 PM
Duration 5mins Strauss 1/2
Entrectinibâ–¼ in Patients with ROS1 Fusion-Positive NSCLC: Updated Efficacy and Safety Analysis
Fan Y, Drilon A, Chui C-H, Bowles D, Loong HHF, Siena S, Goto K, Krzakowski M, Ahn M-J, Murakami H, Dziadziuszko R, Zeuner H, Pitcher B, Cheick D, Krebs M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar